Thought Leadership
Email Page
What High Court's Kisor Ruling Means for FDA Decisions
July 16, 2019
Chad Landmon, Alex Alfano, and Ashton Copeland
Law360

Axinn partner Chad Landmon, associate Alex Alfano, and summer associate Ashton Copeland authored the Law360 article, "What High Court's Kisor Ruling Means for FDA Decisions."

Click here to access the article. A subscription is required.

By using the Axinn, Veltrop & Harkrider LLP website with cookies enabled on your browser, you agree to our use of cookies during your browsing experience. Learn more about our privacy policy.